Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting
Acceleron Pharma Inc. (XLRN)
Last acceleron pharma inc. earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.acceleronpharma.com/investor-relations
Company Research
Source: Business Wire
– Updated results from MEDALIST Phase 3 trial show 47.1% of patients with anemia associated with myelodysplastic syndromes treated with luspatercept achieved red blood cell transfusion independence for = 8 weeks and median total duration of clinical benefit was 83.6 weeks for patients responding to luspatercept as of a January 2019 data cutoff date –– In the BELIEVE Phase 3 trial, beta-thalassemia patients who were luspatercept responders had durable clinical benefit over the 64.1-week follow-up period –– Interim results from the ongoing Phase 2 trial of luspatercept in patients with anemia associated with myelofibrosis suggest clinically meaningful activity, with 32% to 53% of transfusion-dependent patients achieving responses when treated in combination with ruxolitinib – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare disease
Show less
Read more
Impact Snapshot
Event Time:
XLRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XLRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XLRN alerts
High impacting Acceleron Pharma Inc. news events
Weekly update
A roundup of the hottest topics